🚀 Immune checkpoint inhibitors have transformed cancer care—but they come with a cardiovascular shadow.
A new International Cardio-Oncology Society (IC-OS) position statement offers the clearest guidance yet on myocarditis, pericarditis, arrhythmias, ACS, and noninflammatory HF linked to ICI therapy. 🫀💡
Key insights include:
• Early recognition with troponin, ECG, and CMR 🧪📊
• Smoldering vs. nonsevere vs. fulminant myocarditis distinctions 🔍
• Steroid-first management and the evolving role of abatacept + JAK inhibitors 💊
• Nuanced approaches to ICI rechallenge when cancer control demands it 🔄🎯
• The essential role of multidisciplinary cardio-oncology teams 🤝
This is a must-read for anyone navigating the intersection of oncology, cardiology, and immunotherapy. 🌐🔥